Table.
Participant demographics
| TwinsUK: rheumatoid arthritis unaffected (n=1650) |
SCREEN-RA |
|||
|---|---|---|---|---|
| Pre-rheumatoid arthritis (n=83) | FDR controls (n=50) | |||
| Age, years | 63 (56–69) | 58 (50–66) | 55 (47–62) | |
| Sex | ||||
| Women | 1535 (93%) | 74 (89%) | 39 (78%) | |
| Men | 115 (7%) | 9 (11%) | 11 (22%) | |
| BMI | 25 (23–29) | 24 (22–27) | 24 (22–27) | |
| ACPA positive | 9* (2%) | 38 (46%) | 0 | |
| Rheumatoid factor positive | 35*(7%) | 28 (34%) | 0 | |
| Shared epitope positive | .. | 42 (51%) | 32 (64%) | |
| ACPA and rheumatoid factor positive | 1 (<1%) | 6 (7%) | 0 | |
| Current smoker | 567 (34%) | 16 (19%) | 11 (22%) | |
| Antibiotic use within the past month | 66 (4%) | .. | .. | |
| Caucasian; northern European | 1650 (100%) | 83 (100%) | 50 (100%) | |
| Swollen joints | .. | 1 (0–3) | 0 (0–1) | |
| Tender joints | .. | 1 (0–2) | 0 (0–1) | |
Data are median (IQR), or n (%). ACPA positivity was defined as a concentration of greater than 5 uL/mL. Rheumatoid factor positivity was defined as a concentration of greater than 15 uL/mL. FDR=false discovery rate. BMI=body-mass index. ACPA=anti-citrullinated protein antibody.
*
Serum samples analysed for 500 TwinsUK participants, including those with highest polygenic risk scores.